Glanzmann thrombasthenia: genes and variants
Explore variant evidence for Glanzmann thrombasthenia across 2 analyzed proteins (ITGA2B, ITGB3). Linked ClinVar records include 135 pathogenic or likely pathogenic variants, 319 variants of uncertain significance and 5 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Glanzmann thrombasthenia
ITGA2B: Integrin alpha-IIb
Together with ITGB3, it forms the major platelet fibrinogen receptor that becomes activated during platelet stimulation and drives aggregation. Biallelic loss-of-function variants cause Glanzmann thrombasthenia, a severe inherited platelet-aggregation disorder.
74 ClinVar pathogenic / likely pathogenic and 259 uncertain variants in ITGA2B have source records linked to Glanzmann thrombasthenia. Association strength is not clinical gene validity.
ITGB3: Integrin beta-3
In platelets it pairs with ITGA2B to bind fibrinogen and mediate aggregation, while in other cells it forms integrins involved in matrix adhesion and signaling. Biallelic loss-of-function variants cause Glanzmann thrombasthenia.
61 ClinVar pathogenic / likely pathogenic and 65 uncertain variants in ITGB3 have source records linked to Glanzmann thrombasthenia. Association strength is not clinical gene validity.
Where Glanzmann thrombasthenia variants cluster
- ITGB3 VWFA (positions 135–377): 34 of 61 ClinVar pathogenic / likely pathogenic variants, 1.8× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Glanzmann thrombasthenia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| ITGA2B P176A | 176 | Extracellular | Pathogenic / likely pathogenic (★★★) |
| ITGA2B L214R | 214 | FG-GAP 3 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 L143W | 143 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 L143S | 143 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 M144R | 144 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D145Y | 145 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D145N | 145 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 Y216H | 216 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 Y216C | 216 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 R240Q | 240 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 R240W | 240 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D243H | 243 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D243V | 243 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 Q254R | 254 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 Q254K | 254 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D314Y | 314 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D314A | 314 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 Y344C | 344 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 Y344S | 344 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C532Y | 532 | I-EGF 2 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C532F | 532 | I-EGF 2 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C532R | 532 | I-EGF 2 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C547W | 547 | I-EGF 2 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C601G | 601 | I-EGF 4 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C601R | 601 | I-EGF 4 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 G605D | 605 | I-EGF 4 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B G159V | 159 | FG-GAP 2 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B G159S | 159 | FG-GAP 2 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B P176H | 176 | Extracellular | Pathogenic / likely pathogenic (★★★) |
| ITGA2B L214P | 214 | FG-GAP 3 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B G321W | 321 | FG-GAP 5 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B G321V | 321 | FG-GAP 5 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C547G | 547 | I-EGF 2 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 G605S | 605 | I-EGF 4 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B Y174H | 174 | Extracellular | Pathogenic / likely pathogenic (★★★) |
| ITGA2B P176L | 176 | Extracellular | Pathogenic / likely pathogenic (★★★) |
| ITGA2B A216V | 216 | FG-GAP 3 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B F320S | 320 | FG-GAP 5 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B L452R | 452 | FG-GAP 7 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B R551W | 551 | Extracellular | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C39G | 39 | PSI | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D139H | 139 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 Y141C | 141 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 M150V | 150 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C210S | 210 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 V219M | 219 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 L222P | 222 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 D250G | 250 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 H281P | 281 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 G286R | 286 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 L288P | 288 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 I330N | 330 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 N365S | 365 | VWFA | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C400Y | 400 | Extracellular | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C483Y | 483 | I-EGF 1 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C549S | 549 | I-EGF 3 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 G566D | 566 | I-EGF 3 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C568R | 568 | I-EGF 3 | Pathogenic / likely pathogenic (★★★) |
| ITGB3 C624Y | 624 | I-EGF 4 | Pathogenic / likely pathogenic (★★★) |
| ITGA2B P157H | 157 | FG-GAP 2 | Pathogenic / likely pathogenic (★★★) |
Showing 60 of 135.
Uncertain variants prioritized for review in Glanzmann thrombasthenia
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| ITGB3 C547Y | 547 | I-EGF 2 | Uncertain (★★★) | +7: 3 other pathogenic changes within 3 positions; C547G at the same position is pathogenic; seen in 6.9e-07 of gnomAD DNA copies; REVEL 0.973 |
| ITGB3 C568Y | 568 | I-EGF 3 | Uncertain (★) | +7: 2 other pathogenic changes within 3 positions; C568R at the same position is pathogenic; seen in 0 of gnomAD DNA copies; REVEL 0.962 |
| ITGA2B A341V | 341 | FG-GAP 5 | Uncertain (★★★) | +6: 2 other pathogenic changes within 3 positions; A341T at the same position is pathogenic; seen in 0 of gnomAD DNA copies; REVEL 0.764 |
| ITGA2B G296E | 296 | FG-GAP 4 | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; G296R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.96 |
| ITGA2B R358C | 358 | FG-GAP 5 | Uncertain (★★★) | +6: 2 other pathogenic changes within 3 positions; R358H at the same position is pathogenic; seen in 1.4e-06 of gnomAD DNA copies; REVEL 0.656 |
Which prediction tools work for Glanzmann thrombasthenia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 96 out of 100
- VARITY: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 93 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 93 out of 100
- REVEL: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 92 out of 100
- EVE: 92 out of 100
- phyloP: 91 out of 100
- SIFT: 88 out of 100
- PolyPhen-2: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phastCons: 86 out of 100
- MetaSVM: 85 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 55 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 46 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Glanzmann thrombasthenia
- Hypertrophic cardiomyopathy, also linked to ITGA2B and ITGB3
- Noonan syndrome, also linked to ITGA2B and ITGB3
- Costello syndrome, also linked to ITGA2B and ITGB3
- Myocardial infarction, also linked to ITGA2B and ITGB3
- Bleeding disorder, platelet-type, 24, also linked to ITGB3
Frequently asked questions
Which genes have records linked to Glanzmann thrombasthenia?
This view contains 2 analyzed proteins: ITGA2B, ITGB3. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 135 pathogenic or likely pathogenic variants, 319 variants of uncertain significance and 5 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 5 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 569 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center